A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer

Completed · Phase 1

Conditions studied: Neuroendocrine Prostate Cancer

In brief

To evaluate the safety and tolerability of Tarlatamab and will determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).

Key facts

Study ID
NCT04702737
Run by
Amgen
People needed
41
Starts
2021-06-10
Expected to finish
2024-07-22
Last updated by the study team
2025-09-12

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.